fgfr2 inhibitor,rly-4008
cogent biosciences,relay therapeutics
['rly-4008', 'solid tumor', 'fgfr2 inhibitor']
 presents phase i of fgfr2 inhibitor (rly-4008) in cholangio &amp; solid tumors. no mtd. glad pan-fdfri refractory fgfr2+ fusion cholangio included w orr 21% w 70mg or greater &amp; 11% &lt;70mg. discussed potential for strategic sequencing #asco23 
Hematology/Oncology Fellow @ClevelandClinic. Interested in GI oncology. Internist via @CCF_IMCHIEFS. IUSM graduate. She/her. Tweets are my own.